Yahoo Web Search

Search results

1. • 

     Drugmakers go under the skin, skirting early US Medicare price negotiations

     Reuters via Yahoo Finance· 10 months ago

     Injectable versions of some widely-used cancer drugs including Johnson & Johnson's blockbuster...

2. • 

     J&J's (JNJ) Q4 Earnings Beat, Darzalex, Stelara Drive Sales

     Zacks via Yahoo Finance· 4 months ago

     Johnson & Johnson’s JNJ fourth-quarter 2023 earnings came in at $2.29 per share, which beat the...

3. • 

     Halozyme (HALO) Q4 Earnings Top, Revenues Miss, Stock Down

     Zacks via Yahoo Finance· 1 year ago

     Halozyme Therapeutics, Inc. HALO reported fourth-quarter 2022 adjusted earnings of 48 cents per...

4. • 

     Halozyme's (HALO) Q1 Earnings Beat, Revenues Lag Estimates

     Zacks via Yahoo Finance· 2 weeks ago

     Halozyme Therapeutics, Inc. HALO reported first-quarter 2024 adjusted earnings of 79 cents per...

5. • 

     Genmab: Growth Is Still a Better Choice

     GuruFocus.com via Yahoo Finance· 3 months ago

     Genmab AS (NASDAQ:GMAB) is one of the largest Danish pharmaceutical companies focused on developing medicines to treat patients with cancer, multiple...

6. • 

     Halozyme Therapeutics (HALO) Down 10.6% Since Last Earnings Report: Can It Rebound?

     Zacks via Yahoo Finance· 2 years ago

     It has been about a month since the last earnings report for Halozyme Therapeutics (HALO). Shares...

7. • 

     Will J&J (JNJ) Pharma Unit Outperform Market & Drive Q1 Results?

     Zacks via Yahoo Finance· 1 year ago

     In J&J's (JNJ) Pharma segment, its oncology drug, Darzalex as well as a psoriasis treatment, Stelara...

8. • 

     J&J (JNJ) Q1 Earnings Beat Estimates, Sales Miss, MedTech Soft

     Zacks via Yahoo Finance· 1 month ago

     Johnson & Johnson’s JNJ first-quarter 2024 earnings came in at $2.71 per share, which beat the Zacks...

9. • 

     J&J (JNJ) Q2 Earnings & Sales Top, '23 View Upped, Stock Jumps

     Zacks via Yahoo Finance· 10 months ago

     Johnson & Johnson’s JNJ second-quarter 2023 earnings came in at $2.80 per share, which beat the...

10. • 

      Here's Why it is a Good Time to Buy J&J's (JNJ) Stock Now

      Zacks via Yahoo Finance· 9 months ago

      J&J's (JNJ) Pharma sales are being driven by key drugs like Darzalex and new products. J&J's Pharma...